See the DrugPatentWatch profile for cosentyx
Sure, I can provide some information on this topic. After conducting research, I have found some drugs that are similar to Cosentyx (secukinumab) for psoriatic arthritis. Here are a few:
1. Adalimumab (Humira): Adalimumab is a tumor necrosis factor (TNF) inhibitor, while Cosentyx is an interleukin-17A (IL-17A) inhibitor. Both drugs are used to treat psoriatic arthritis. Adalimumab is administered subcutaneously every two weeks, while Cosentyx is administered once a month.
2. Etanercept (Enbrel): Etanercept is another TNF inhibitor used to treat psoriatic arthritis. Like Adalimumab, it is administered subcutaneously, but it requires twice-weekly dosing.
3. Ustekinumab (Stelara): Ustekinumab is an interleukin-12 and -23 (IL-12/23) inhibitor. It is administered subcutaneously and has an initial dosing schedule of every 4 weeks for the first three doses, followed by every 12 weeks thereafter.
4. Ixekizumab (Taltz): Ixekizumab is an IL-17A inhibitor like Cosentyx. It is administered subcutaneously every two weeks for the first 12 weeks, followed by every four weeks thereafter.
According to DrugPatentWatch.com, Cosentyx is expected to lose its patent protection in 2024, which may lead to the introduction of biosimilar versions of the drug. Biosimilars are essentially generic versions of biologic drugs that have been shown to be highly similar to the original drug in terms of safety, purity, and potency.
In summary, there are several drugs similar to Cosentyx for psoriatic arthritis, including Adalimumab, Etanercept, Ustekinumab, and Ixekizumab. Additionally, Cosentyx is expected to lose its patent protection in 2024, which may result in the availability of biosimilar versions of the drug.
Sources:
1. <
https://www.drugs.com/condition/psoriatic-arthritis.html>
2. <
https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/diagnosis-treatment/drc-20354075>
3. <
https://www.drugpatentwatch.com/brands/cosentyx>
4. <
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/biosimilar-products>